News

As per the terms of the collaboration deal, the companies will supply their respective products and equally share the trial costs. Genentech will manage the trial, which expects

The final agreement will be signed, inter alia, subject to the completion of an initial clinical trial in the technology to the satisfaction of Therapix, and the completion

"We selected Theradex to assist the Company in pursuing our proposed studies in Hodgkin’s Lymphoma because of Theradex’s invaluable assistance in finalizing our prior IND with the FDA

As part of the collaboration, Kangstem Biotech will provide iNSCs to ORIG3N for use in its disease-modeling platform. Kangstem Biotech has developed a novel approach to generating patient-specific

This UCART19 clinical trial is sponsored by Servier in close collaboration with Pfizer. The pediatric Phase I is an open label, non-comparative, monocenter study to evaluate the safety

The growth, which represents a compound annual growth rate of 13.6%, will take place in the US, France, Germany, Italy, Spain, the UK, and Japan, the seven major

The company secured orphan drug designation from the US Food and Drug Administration for Epidiolex (cannabidiol or CBD) to treat IS. A two-part pivotal Phase 3 study is

The agreement is in connection with the divestiture process mandated by the US Federal Trade Commission (FTC) in relation toTeva’s $40.5bn acquisition of Allergan’s generic drugs portfolio. Impax

Under the double-blind, double-dummy, parallel group FULFIL study, 1,810 patients were randomized to receive either GSK’s fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or budesonide/formoterol. The study met its objectives, with the